caa a22 4500 477057764 CHVBK 20180405111351.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/s002280050124 doi (NATIONALLICENCE)springer-10.1007/s002280050124 Differences in the response of serum lipoproteins to fenofibrate between women and men with primary hypercholesterolaemia [Elektronische Daten] [T. Sudhop, D. Lütjohann, C. Ratman, J. von Bergmann, K. von Bergmann] Objective: We studied possible sex differences of the effect of fenofibrate on serum lipoproteins. Twenty-three patients with primary hypercholesterolaemia (10 postmenopausal women and 13 aged-matched men) were treated with slow-release fenofibrate for 96 weeks. Results: Steady state lipoprotein concentrations were reached after 12 and 24 weeks of treatment in women and men, respectively. During the subsequent follow-up the lipoprotein concentrations remained constant. In women total and low-density lipoprotein (LDL) cholesterol decreased from 299 to 234 mg⋅dl−1 and from 210 to 151 mg⋅dl−1, respectively, and in men from 265 to 233 mg⋅dl−1 and from 192 to 160 mg⋅dl−1. The decrease in triglycerides was also more pronounced in women (−42%) than in men (−18%). High-density lipoprotein (HDL) cholesterol increased significantly in women from 53 to 63 mg⋅dl−1 but not in men (45 to 50 mg⋅dl−1). Since the changes in LDL and HDL cholesterol occurred in opposite directions, the decrease in LDL/HDL cholesterol ratio was accentuated in both groups. However, this ratio was decreased almost twofold in women (−41%) compared to men (−23%). Although the serum concentrations of fenofibric acid were 1.3-fold higher in women than in men, which was probably due to the higher body weight in men (1.2-fold), this difference can hardly explain the favorable effect on lipoproteins in women. Conclusion: The present study indicates that fenofibrate might be very effective by reducing the concentrations of atherogenic lipoproteins in postmenopausal women. Springer-Verlag Berlin Heidelberg, 1996 Key words Hyperlipoproteinaemia nationallicence Fenofibrate nationallicence fenofibric acid nationallicence sex differences nationallicence long-term treatment nationallicence Sudhop T. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut Lütjohann D. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut Ratman C. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut von Bergmann J. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut von Bergmann K. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut https://doi.org/10.1007/s002280050124 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050124 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sudhop T. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut NATIONALLICENCE 700 1- Lütjohann D. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut NATIONALLICENCE 700 1- Ratman C. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut NATIONALLICENCE 700 1- von Bergmann J. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut NATIONALLICENCE 700 1- von Bergmann K. Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer